Skip to content
approvedBone & Joint

Teriparatide

Also known as: Forteo, PTH(1-34), Recombinant Human Parathyroid Hormone, rhPTH(1-34), Teribone

Teriparatide (Forteo) is the recombinant form of the first 34 amino acids of human parathyroid hormone — the biologically active fragment responsible for calcium homeostasis and bone remodeling. FDA-approved in 2002 for severe osteoporosis, it was the first anabolic (bone-building) osteoporosis therapy, fundamentally changing treatment by stimulating new bone formation rather than merely slowing resorption. Administered as a daily subcutaneous injection for up to 2 years, it reduces vertebral fractures by 65% and non-vertebral fractures by 53%.

4 cited references·5 researched benefits

Quick Answer

Teriparatide (Forteo) is the recombinant 1-34 fragment of human parathyroid hormone and the first FDA-approved anabolic osteoporosis therapy. Unlike bisphosphonates that slow bone loss, teriparatide actively builds new bone by stimulating osteoblasts. Daily subcutaneous injection for up to 24 months reduces vertebral fractures by 65% and non-vertebral fractures by 53%. It carries a black box warning for osteosarcoma risk based on rat studies.

Key Facts

Mechanism
Teriparatide binds to the PTH/PTHrP receptor (PTH1R), a class B GPCR expressed on osteoblasts, renal tubular cells, and other tissues. The key to its anabolic effect is intermittent exposure: daily pulsatile administration activates cAMP/PKA and Wnt/beta-catenin signaling in osteoblasts, promoting their differentiation, survival (via anti-apoptotic Bcl-2 upregulation), and activity. This increases bone formation markers (P1NP, osteocalcin) within weeks. Intermittent PTH also suppresses sclerostin (a Wnt pathway inhibitor) produced by osteocytes, further amplifying the osteoanabolic signal. The "anabolic window" occurs because osteoblast activation precedes osteoclast activation by several months, creating a net gain in bone mass. Continuous PTH exposure (as in hyperparathyroidism) has the opposite effect, favoring resorption.
Research Status
approved
Half-Life
~1 hour (subcutaneous)
Molecular Formula
C₁₈₁H₂₉₁N₅₅O₅₁S₂
Primary Use
Bone & Joint
Table of Contents

Benefits

  • Reduces vertebral fractures by 65% and non-vertebral fractures by 53% in the landmark Fracture Prevention Trial (FPT)strong
  • First true anabolic bone agent — stimulates new bone formation via osteoblast activation, increasing both cortical and trabecular bone densitystrong
  • Increases lumbar spine BMD by 9-13% and femoral neck BMD by 3-6% over 18-24 months of treatmentstrong
  • Improves bone microarchitecture — increases trabecular number, thickness, and connectivity beyond what BMD alone capturesstrong
  • Accelerates fracture healing in clinical studies — reduces time to cortical bridging and improves healing outcomes in distal radius and hip fracturesmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection (Forteo pen)20 mcgOnce dailyStandard FDA-approved dose. Administer in the thigh or abdominal wall. Maximum treatment duration is 24 months due to osteosarcoma precaution. Must be refrigerated.
Subcutaneous injection (fracture healing, off-label)20 mcgOnce daily for 8-12 weeksInvestigational use for accelerating fracture repair. Some orthopedic studies use 6-12 week courses following surgical fixation of osteoporotic fractures.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hypercalcemia — transient increases in serum calcium occur in 11% of patients, usually mild and peaking 4-6 hours post-injectioncommon
  • Orthostatic hypotension and dizziness — reported in 5-9% of patients, typically within 4 hours of injection; first doses should be given where patient can sit or lie downcommon
  • Nausea — reported in 8-14% of patients, more common in early treatment and usually transientcommon
  • Leg cramps and arthralgia — musculoskeletal complaints in 3-10% of patientscommon
  • Injection site reactions — erythema, pain, or bruising at the injection sitecommon
  • Osteosarcoma (black box warning) — dose-dependent osteosarcoma observed in Fischer 344 rats treated at high doses for near-lifetime duration; not confirmed in humans despite post-marketing surveillance of >1 million patient-years, but treatment limited to 2 years as a precautionserious

Frequently Asked Questions

Why is teriparatide limited to 2 years of treatment?
The 2-year limit stems from preclinical rat studies where Fischer 344 rats treated with teriparatide at doses 3-58 times the human dose for nearly their entire lifespan (2 years — equivalent to most of a rat's life) developed dose-dependent osteosarcoma. Although this finding has never been replicated in humans — the FDA's post-marketing surveillance database (OSAR) found no increased osteosarcoma signal after >1 million patient-years of exposure — the black box warning and 2-year limit remain as a precaution. After stopping teriparatide, patients must transition to an anti-resorptive agent (typically a bisphosphonate or denosumab) to maintain the gains in bone density.
How does teriparatide differ from abaloparatide?
Both are anabolic bone agents that work through the PTH1R receptor, but teriparatide is the PTH(1-34) fragment while abaloparatide is a synthetic analog of PTHrP(1-34) with modifications for improved receptor selectivity. Abaloparatide preferentially activates the RG receptor conformation of PTH1R, producing a more transient cAMP response that may explain its somewhat lower incidence of hypercalcemia (3.4% vs 6.4%). The ACTIVE trial showed abaloparatide may have slightly better hip fracture reduction, while teriparatide has more long-term data and is available as a biosimilar at lower cost.
What happens when you stop teriparatide?
Bone density gains from teriparatide are progressively lost if not followed by anti-resorptive therapy. Studies show that within 12-18 months of discontinuation without follow-up treatment, BMD returns toward baseline levels. This is because the newly formed bone undergoes normal remodeling and resorption without continued anabolic stimulus. Current guidelines strongly recommend transitioning to a bisphosphonate (alendronate, zoledronic acid) or denosumab immediately after completing the 2-year teriparatide course to consolidate and maintain bone gains.
Can teriparatide be used for glucocorticoid-induced osteoporosis?
Yes, teriparatide is FDA-approved for glucocorticoid-induced osteoporosis (GIO) in men and women at high fracture risk. The pivotal GIO trial demonstrated that teriparatide was superior to alendronate in increasing vertebral BMD (7.2% vs 3.4% at 18 months) and reducing new vertebral fractures (0.6% vs 6.1%). This is because glucocorticoids primarily suppress osteoblast function, and teriparatide directly counters this by stimulating osteoblast differentiation and activity. It is considered the preferred treatment for severe GIO with existing fractures.
Is there a generic or biosimilar version of Forteo?
Yes, the first teriparatide biosimilar was approved by the FDA in 2023, and additional biosimilars have entered the market, significantly reducing costs. The branded Forteo pen previously cost approximately $3,500 per month, while biosimilar versions are substantially less expensive. All approved biosimilars demonstrate equivalent efficacy and safety in clinical studies. The availability of biosimilars has improved patient access to anabolic osteoporosis therapy.

References

  1. 1
    Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis(2001)PubMed ↗
  2. 2
    Teriparatide for treatment of osteoporosis: clinical efficacy and safety ten years after first approval(2011)PubMed ↗
  3. 3
    Osteosarcoma in the Forteo Patient Registry: analysis of incidence and risk factors(2016)PubMed ↗
  4. 4
    Comparison of the effects of teriparatide and alendronate on bone mineral density in glucocorticoid-induced osteoporosis(2007)PubMed ↗

Latest Research

Last updated: 2026-02-19